Frequency Therapeutics CEO David Lucchino (L) and Korro Bio CEO Ram Aiyar
July 14, 2023 06:54 AM EDTUpdated 09:45 AM
Startups
Deals

Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Kyle LaHucik

Senior Reporter

Re­verse merg­ers are in vogue, and Fre­quen­cy Ther­a­peu­tics will join the bo­nan­za, with RNA edit­ing start­up Ko­r­ro Bio ex­pect­ed to take its spot on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times